Jan 14, 2021 / 03:00PM GMT
Seiji Wakao - JPMorgan Chase & Co, Research Division - VP
Good morning, everyone. Welcome to the JPMorgan Healthcare Conference. I'm Seiji Wakao, Japan pharma analyst in JPMorgan. And it's my pleasure to introduce Chris Cargill, CFO with Sosei; and Miles Congreve, Chief Scientific Officer, will join for Q&A session. Welcome them to the conference. (Operator Instructions)
With that, let me turn it over to Chris. Please go ahead. Chris?
Chris Cargill - Sosei Group Corporation - Group COO & CFO
Thank you very much, Wakao-san. I'm beginning on the cover page. And good morning, and welcome to the Sosei Heptares presentation at the 39th Annual JPMorgan Healthcare Conference. Despite the COVID environment, it's wonderful to be able to present virtually. I'd like to thank our friends again at JPMorgan for their continued support and for inviting us to present back again this year.
This morning, I'm going to give you a brief overview of our drug discovery platform and core capabilities. In addition to updating on the excellent progress that
Sosei Group Corp at JPMorgan Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot